Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R Moriggl
Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Clinical and Prognostic Significance of E1a2 BCR-ABL1 Transcript Subtype in Chronic Myeloid Leukemia
Blood Cancer Journal
Oncology
Hematology
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
Molecular Therapy - Nucleic Acids
Drug Discovery
Molecular Medicine
The Benefit of Quality Control Charts (QCC) for Routine Quantitative BCR-ABL1 Monitoring in Chronic Myeloid Leukemia
PLoS ONE
Multidisciplinary
Requirement of SRC Kinases Lyn, HCK and FGR for BCR-ABL1-induced B-Lymphoblastic Leukemia but Not Chronic Myeloid Leukemia
Nature Genetics
Genetics
Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model
Haematologica
Hematology
The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
A Novel BCR-ABL1 Fusion Gene With Genetic Heterogeneity Indicates a Good Prognosis in a Chronic Myeloid Leukemia Case
Molecular Cytogenetics
Biochemistry
Molecular Medicine
Genetics
Molecular Biology
MPT0B169, a New Antitubulin Agent, Inhibits BCR-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
PLoS ONE
Multidisciplinary
Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia
Oncotarget
Oncology
